The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.
Cefalo, G., Massimino, M., Ruggiero, A., Barone, G., Ridola, V., Spreafico, F., Potepan, P., Abate, M., Mascarin, M., Garrè, M., Perilongo, G., Madon, E., Colosimo, C., Riccardi, R., Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial, <<NEURO-ONCOLOGY>>, N/A; 16 (5): 748-753. [doi:10.1093/neuonc/not320] [http://hdl.handle.net/10807/55974]
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial
Ruggiero, Antonio;Barone, Giuseppe;Ridola, Vita;Colosimo, Cesare;Riccardi, Riccardo
2014
Abstract
The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
